Answers are grounded in this paper and cite their sources.
Antiangiogenic therapy is the main method of choice in the treatment of a number of retinal diseases. IVI injections with an anti-VEGF drug, as well as IVV implants of dexamethasone ozurdex, were widely used. Considering that currently the effect of these drugs on cataractogenesis is poorly understood, work in this direction is strategically important for understanding the morphological features of the development of cataracts of a post-injection etiological nature. Objective. To study the dynamics of lens thickness against the background of intravitreal administration of aflibercept and dexamethasone depot. Material and methods. 220 eyes were included in the study. Depending on the drug used, the first group included 100 eyes that received IVI of aflibercept, the second group included 20 eyes that received an intravitreally injected deхamethasone ozurdex implant, the control (third) group consisted of 100 eyes. Results. The dynamics of changes in lens thickness was recorded in the groups of patients who received Ozurdex between 3 and 6 months (0.012), which reflects a slow increase in lens thickness in this group. Conclusion. In patients who received aflibercept, there was no statistically significant difference in lens thickness after 3 and 6 months. In the dexamethasone depot group, a statistically significant increase in lens thickness was noted at 3 and 6 months compared with the control group and the aflibercept group.
No takes yet. Share an insight, caveat, or question.
Алхарки et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: